Lv4
440 积分 2024-09-24 加入
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
1个月前
已完结
Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment
1个月前
已完结
Real-World Quality-of-Life Data in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors Using Four Assessment Tools
1个月前
已完结
Computed tomography‑based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors
1个月前
已完结
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
2个月前
已完结
MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy
2个月前
已完结
Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3
2个月前
已关闭
Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor
2个月前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
